

Preliminary Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-23 (canceled)

Claim 24 (new): A composition comprising the carboxylate form of a camptothecin drug associated with at least one organic cationic molecule having a net positive charge wherein the molar ratio of the organic cationic molecule to the carboxylate is at least about 1:1 wherein said composition is substantially free of the lactone form of said camptothecin.

Claim 25 (new): The composition of claim 24 wherein said organic cationic molecule is a cationic amphiphile and/or a cationic polymer.

Claim 26 (new): The composition of claim 25, wherein said cationic amphiphile is lipid, lysolipid or pegylated lipid.

Claim 27 (new): The composition of claim 25, wherein said cationic amphiphile has a tertiary amino or quaternary ammonium compound.

Claim 28 (new): The composition of claim 27, wherein said tertiary amino compound is N-[1-(2,3-diacetoxy)propyl]-N,N-dimethylamine.

Claim 29 (new): The composition of claim 27, wherein said quaternary ammonium compound is N-[1-(2,3-diacetoxy)propyl]-N,N,N-trimethyl ammonium.

Claim 30 (new): The composition of claim 25, wherein said cationic polymer is a polyelectrolyte, an acid of polyallylamine, an acid of polyethylene imine, a polymeric sugar or a polyamine with a molecular weight between about 5 and about 500 kDa.

Claim 31 (new): The composition of claim 24, further comprising at least one anionic and/or neutral amphiphile.

Claim 32 (new): The composition of claim 31, wherein said anionic and/or neutral amphiphile is a sterol or a lipid.

Claim 33 (new): The composition of claim 32, wherein said sterol is cholesterol.

Claim 34 (new): The composition of claim 32, wherein said lipid is phospholipid, lysolipid, lysophospholipid, sphingolipid, or pegylated lipid with a net negative or neutral charge.

Claim 35 (new): The composition of claim 34, wherein said phospholipid is diacylphosphatidylcholine.

Claim 36 (new): A colloidal nanoaggregate comprising a composition of claim 24.

Claim 37 (new): The nanoaggregate of claim 36 having an overall positive charge.

Claim 38 (new): The nanoaggregate of claim 37, further comprising at least one anionic and/or neutral amphiphile.

Claim 39 (new): The nanoaggregate of claim 38, wherein said anionic and/or neutral amphiphile is a sterol or a lipid.

Claim 40 (new): The nanoaggregate of claim 39, wherein said sterol is cholesterol.

Claim 41 (new): The nanoaggregate of claim 39, wherein said lipid is phospholipid, lysolipid, lysophospholipid, sphingolipid, or pegylated lipid with a net negative or neutral charge.

Claim 42 (new): The nanoaggregate of claim 41, wherein the phospholipid is diacylphosphatidylcholine.

Claim 43 (new): The nanoaggregate of claim 38, comprising an excess of positively charged moieties of at least about 20 % in the outer molecular layer.

Claim 44 (new): The nanoaggregate of claim 38, comprising an excess of positively charged moieties of at least about 30 % in the outer molecular layer.

Claim 45 (new): The nanoaggregate of claim 38, comprising an excess of positively charged moieties of at least about 40 % in the outer molecular layer.

Claim 46 (new): The nanoaggregate of claim 38, which is present as an emulsion droplet, a micelle, a liposome, a nanoparticle, or a nanocapsule.

Claim 47 (new): The nanoaggregate of claim 46, comprising about 0.1 to about 50 mol% of a camptothecin drug or a derivative thereof.

Claim 48 (new): The nanoaggregate of claim 47, further comprising a cryoprotectant which is selected from a sugar, an alcohol, or a combination thereof.

Claim 49 (new): The nanoaggregate of claim 48, wherein said cryoprotectant is trehalose, maltose, sucrose, glucose, lactose, dextran, mannitol, or sorbitol.

Claim 50 (new): A pharmaceutical preparation comprising a pharmaceutically effective amount of the colloidal nanoaggregate of claim 36 together with a pharmaceutically acceptable carrier, diluent, and/or adjuvant.

Claim 51 (new): A method of for treating or preventing a disease associated with enhanced angiogenic activity comprising administering the pharmaceutical composition of claim 50 to a patient in need thereof.

Claim 52 (new): A method of producing the colloidal nanoaggregate of claim 36, comprising:

- a) providing a camptothecin drug, preferably as a salt;
- b) associating said camptotecin drug in its carboxylate form with a cationic amphiphile having a net positive charge and optionally at least one further amphiphile which has a net positive, negative and/or neutral charge; and
- c) forming a colloidal nanoaggregate.

Claim 53 (new): The method of claim 52, wherein steps b) and c) comprise forming said nanoaggregate by a homogenisation, a lipid film or by a solvent injection procedure.

Claim 54 (new): A pharmaceutical preparation comprising a pharmaceutically effective amount of the composition of claim 24 together with a pharmaceutically acceptable carrier, diluent and/or adjuvant.

Claim 55 (new): A method of treating or preventing a disease associated with enhanced angiogenic activity comprising administering the pharmaceutical composition of claim 54 to a patient in need thereof.

Claim 56 (new): The method of claim 51, wherein the disease associated with enhanced angiogenic activity is selected from the group consisting of cancer, inflammatory diseases,

diabetic retinopathy, rheumatoid arthritis, inflammation, dermatitis, psoriasis, stomach ulcers and macular degeneration.

Claim 57 (new): The method of claim 56 wherein the disease associated with enhanced angiogenic activity is cancer.

Claim 58 (new): The method of claim 55, wherein the disease associated with enhanced angiogenic activity is selected from the group consisting of cancer, inflammatory diseases, diabetic retinopathy, rheumatoid arthritis, inflammation, dermatitis, psoriasis, stomach ulcers and macular degeneration.

Claim 59 (new): The method of claim 58 wherein the disease associated with enhanced angiogenic activity is cancer.